▲ +291.37% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aptinyx in the last 3 months. The average price target is $12.25, with a high forecast of $15.00 and a low forecast of $7.00. The average price target represents a 291.37% upside from the last price of $3.13.
The current consensus among 7 contributing investment analysts is to buy stock in Aptinyx.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.